Request Demo
Last update 18 Oct 2025
Semaglutide biosimilar(QL Biopharma)
Last update 18 Oct 2025
Overview
Basic Info
Drug Type Recombinant polypeptide, Biosimilar |
Synonyms Semaglutide Biosimilar (Beijing Zhitai Biomedical Technology Co., Ltd.), 司美格鲁肽 生物类似药（北京质肽生物医药科技有限公司）, 司美格鲁肽生物类似药(通化东宝) + [4] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 50953
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Semaglutide biosimilar(QL Biopharma)CTR20240709
在二甲双胍治疗后血糖控制不佳的2型糖尿病患者中比较 ZT001注射液与诺和泰®皮下注射治疗的疗效和安全性：一项多中心、随机、开放、平行对照Ⅲ期临床试验
[Translation] Comparison of the efficacy and safety of ZT001 injection and Novotel® subcutaneous injection in patients with type 2 diabetes with poor glycemic control after metformin treatment: a multicenter, randomized, open, parallel-controlled phase III clinical trial
CTR20230889
在中国男性健康受试者中比较 ZT001 和诺和泰®注射液的药代动力学特征、
安全性和免疫原性的单中心、随机、开放、平行对照的 I 期临床研究
[Translation] A single-center, randomized, open-label, parallel-controlled Phase I clinical study comparing the pharmacokinetic characteristics, safety and immunogenicity of ZT001 and Novotai® injection in healthy Chinese male subjects
CTR20251508
在肥胖受试者中评价司美格鲁肽注射液与Wegovy®的疗效和安全性：一项多中心、随机、开放、平行对照Ⅲ期临床研究
[Translation] Evaluation of the efficacy and safety of semaglutide injection and Wegovy® in obese subjects: a multicenter, randomized, open-label, parallel-controlled phase III clinical study
100 Clinical Results associated with Semaglutide biosimilar(QL Biopharma)
Login to view more data
100 Translational Medicine associated with Semaglutide biosimilar(QL Biopharma)
Login to view more data
100 Patents (Medical) associated with Semaglutide biosimilar(QL Biopharma)
Login to view more data
100 Deals associated with Semaglutide biosimilar(QL Biopharma)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Obesity | Phase 3 | China | 18 Apr 2025 | |
| Obesity | Phase 3 | China | 18 Apr 2025 | |
| Cardiovascular Diseases | Phase 3 | China | 18 Jul 2024 | |
| Diabetes Mellitus, Type 2 | Phase 3 | China | 18 Jul 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free